SAS India Launches SAS 9 After $1bn R&D

Effort
By Hinesh Jethwani
Mumbai, Mar 31, 2004

As part of its global launch initiative, SAS unveiled SAS 9 in India today, culminating a $1 billion R&D effort
spread over the last four years, which is being touted as the biggest launch ever undertaken by the company
in its 28-year history.

SAS 9 is being branded as a faster, more efficient and easier to use solution, than its predecessors. It can
accommodate changing organizational needs without any loss of efficiency. The new platform connects all
SAS applications so they work together transparently, and it also communicates with other data sources and
programs.

Speaking to CXOtoday on the occasion of the launch, Bill Gibson, chief technology officer, SAS Asia Pacific,
said, "Data duplication is a prime issue which has to be dealt with today. As far as extracting data from
disparate sources goes, SAS 9 will effectively create a warehouse, where objects will be standardized for
further statistical analysis. Amongst the early implementers of the SAS 9 platform, is LG Home Shopping
network in Korea, where multiple data sources like SAP, Siebel and Informix were effectively harnessed to
generate results."

SAS 9 consists of an Enterprise ETL server, Intelligent Storage, Enterprise BI server, and SAS solutions.

According to Don Cooper Williams, director - marketing & alliances, SAS Asia-Pacific, "The SAS Intelligence
platform will provide users a single view of the enterprise, originating at the desktop level, and spreading
through the mobile user group right up to the CIO level, unlike others that provide only historical data.”

"SAS 9 includes the SAS Intelligence Platform, a broad set of integrated software for data integration, easy-
to-use business reporting and unparalleled analytics. It also boasts enhancement of the most tightly
integrated optimization and predictive analytics capabilities available, making it easier to answer complex
questions that cannot be addressed by traditional BI,” added Williams.

To support this growth, SAS India aims to expand its direct customer facing team and alliance partners. In
the past, SAS India has made successful inroads into the BFSI, Telecom and Pharmaceutical verticals
where there has been high demand for BI solutions. Going forward, SAS India expects Retail and
Manufacturing to be the additional growth drivers.

Vivek Gokarn, Managing Director & CEO, SAS India said, "SAS 9 will be available to our existing customers
as a free upgrade. We grew 30% last year in 2003 and SAS 9 is expected to drive this pace of growth to an
even higher level by 40%, by actually expanding the market for BI solutions.”

SAS India plans to impart training on SAS 9 solutions to core members of its Alliance partners who in turn
would train close to 100+ executives in implementation across the country through the year.

The future potential of the BI market in India, as per a Frost & Sullivan report is reflected in a CAGR of
 33.9%, wherein India figures will be US $53.2 million by 2008, up from US $15.9
million in 2003.

The company has over 120 installations in the country, and recent key customer
wins include IDBI, Citibank N.A., HSBC and I-Gate.

SAS India currently has consulting alliances with, PricewaterhouseCoopers, TCS, Tata Infotech, Satyam and
MindTree Consulting. Its hardware alliance partners include HP, Sun and IBM.

SAS Drug Development Enchanced

By CXOtoday Staff
Mumbai, Jun 22, 2006

Business Intelligence (BI) vendor SAS has rehashed its flagship life sciences offering SAS Drug
Development, adding new genomic-analysis capabilities in it to make it easier for pharmaceutical companies
to analyze genetic data and incorporate the analysis into new drug applications.

SAS Drug Development is a data management and analysis solution for pharmaceutical, medical device and
biotechnology firms. The vendor has brought in more than 90 processes for genomic and proteomic-specific
molecular analyses, which address the key areas such as genetics, microarrays and proteomics.

The solution apparently provides a customizable, collaborative system for accurate and effective
transformation of potential human drugs, biological products or medical devices from discovery or "proof of
concept" stage into a medical product.

SAS says that the enhancement would also enable organizations to easily incorporate
molecular information into clinical decision-making while allowing life science
organizations to facilitate regulatory compliance, meet requirements for traceability of
analytical results and simplify global collaboration.

Commenting on the new updated version of SAS Drug Development, Dr. Alan Louie,
Research Director at Health Industry Insights, an IDC Company said, "As retrospective
biomarker data begins to be developed for Phase 4 drug testing, these new molecular
analysis capabilities will help to accelerate knowledge capture, analysis and
dissemination across the pharmaceutical development pipeline."
Accenture and SAS Increase Collaboration for BI
By CXOtoday Staff
Mumbai, Mar 6, 2007

Accenture plans to expand its business intelligence

services through increased collaboration with SAS, a
provider of business intelligence (BI) software and
services.

This relationship will help Accenture deliver proven,

repeatable solutions and create additional specialized
capabilities to meet the increased demand for business intelligence services currently provided to clients
through its Accenture Information Management Services (AIMS) organization. For SAS, the relationship will
help accelerate growth of the company's global BI software revenue by leveraging Accenture's investment in
sales, marketing, training, research and development, and expertise in industry and business processes.

"We are clearly seeing an increased demand for business intelligence services as organizations seek higher
performance by collecting and analyzing internal and external data," said Royce Bell, Chief Executive Officer
of Accenture Information Management Services. "By striking a closer relationship with a market-leading
enterprise business intelligence software vendor, we will be able to provide our clients with even more skills
and scale than previously possible."

"Business intelligence solutions and services are clearly the next growth area in information technology. By
leveraging our mutual strengths in software, services and business expertise, we will be better able to take
advantage of global strategic BI opportunities," said Jim Davis, Senior Vice President and Chief Marketing
Officer of SAS. "The breadth of SAS' enterprise intelligence platform and industry focused solutions coupled
with Accenture's ability to provide additional customization, implementation services and global delivery, will
allow customers to address key business and technology pains associated with information management
more quickly and effectively."

Accenture and SAS have successfully teamed together over the last 10 years to provide business
intelligence solutions in the analytics area where companies are seeking to get more insight and value out of
their data, a news release said here today. This expanded relationship will help provide a foundation for
Accenture and SAS to further develop, market, sell and deliver global industry solutions for businesses via a
comprehensive and united approach and set of resources, it added.

According to Henry Morris, Group VP for Integration, Development and Application Strategies at IDC, a
leading analyst firm: "This is a positive move for both companies, each with a demonstrated record of
success in the field of analytics. SAS' commitment to industry solutions and an intelligence platform is
complemented by Accenture's capabilities to explain the benefits to senior executives in the language of
their vertical industry and to provide the skilled personnel required for delivery. The agreement should
benefit both firms and should advance the penetration of analytics across industries and across regions."

Accenture plans to expand its SAS business intelligence capabilities, specifically around the SAS Enterprise
Intelligence Platform, which is the foundation for SAS' targeted business solutions that support enterprise
intelligence, customer intelligence, financial intelligence, supply chain intelligence, as well as technology
solutions for various vertical markets, such as financial services, life sciences, health care, retail,
manufacturing and others.

SAS® SOLUTIONS FOR LIFE SCIENCES

With so many challenges facing the life sciences industry – pricing pressures, pipeline pressures,
impending patent expirations, the soaring cost of developing new drugs – the strength of these
companies as well as the intellectual property they need to improve the health of the public is
being threatened. While the focus seems to be shifting to personalized medicine – the right drug
for the right patient – personalized drugs will most likely mandate significant changes to life
sciences companies' business practices. How can drug companies remain profitable so they can
continue to deliver the best drugs to the public?
In the Spotlight
SAS solutions for life sciences companies optimize the flow of
valuable scientific and operational data within these companies –
helping them bring therapies to market faster and more profitably.
SAS is the only company that offers an end-to-end solution to drive
efficiencies throughout every stage of a drug's lifecycle: from
Preparing for the New Health discovery, through development, commercialization and beyond.
Industry Agenda: How Will it
Impact You?
Watch this on-demand Webcast SAS has a deep commitment to the development of data standards
featuring Newt Gingrich to find in life sciences. Anticipating the movement of the industry and its
out how the 21st century
health services agenda will governing regulatory bodies toward standards, SAS has developed
impact you and your business. technology available today to support the emerging CDISC data
models.

Globally recognized as the industry leader in analytics, the de facto

standard for clinical data analysis, the FDA standard for electronic
HCI 100: 100 Companies by submissions and the choice of 100% percent of the Fortune 500 life
Revenue sciences companies, SAS assures accurate, consistent and reliable
Healthcare Informatics analysis of pharmaceutical research data. By providing a way to
June 2007
(PDF: 426KB) warehouse, manage and analyze your data more efficiently and
effectively, SAS solutions enable life sciences companies to:

• Transform biomedical data into clinical insights quickly.

• Analyze operational data to manage risk and maximize profits.
• Convert intellectual property from discoveries into effective drug treatments.

• Integrate scientific, customer, and operational data to make research and

commercialization programs even more successful.
A suite of solutions to help bring your drug to market successfully
SAS understands that each stage of bringing a drug to market has unique needs. SAS Solutions
for Life Sciences distinctly address the needs of each of these unique stages. Powered by SAS
technology, SAS Solutions for Life Sciences are also designed to work collaboratively, enabling
you to combine solutions as needed in order to bring your drug to market more quickly and
successfully.

• SAS Drug Development provides a centralized, integrated system for managing,

analyzing, reporting and reviewing clinical research information. The solution enables life
sciences organizations to get better products to market faster by more effectively
assessing the safety and efficacy of research compounds and by facilitating collaboration
across trials, phases and therapeutic areas.
• SAS for Life Sciences Sales and Marketing delivers unique customer insights that life
sciences firms can use to execute more efficient marketing, sales and service strategies.
SAS provides proven analytics to power sales and marketing execution.

In addition to SAS Solutions for Life Sciences, SAS offers many other focused solutions and
technologies for your enterprise. Taken together, these solutions give you THE POWER TO
KNOW®.

SAS® AND THE CLINICAL DATA INTERCHANGE STANDARDS CONSORTIUM (CDISC)

The importance of data standards

Data standards are a critical component in the quest to improve global public health.
Inefficiencies in the collection, processing and analysis of patient and health-related information
drive up the cost of research and development for life sciences companies as well as negatively
impact the cost and quality of healthcare delivery for patients and consumers.

In the Spotlight
The solution is to leverage data standards like CDISC to provide
more efficient and effective use of medical information by all
members of the healthcare and life sciences ecosystem.

SAS CDISC participation

Clinical Integration and CDISC
Learn how SAS can help you
standardize clinical information
using CDISC.
With a deep commitment to the development and implementation of
data standards in life sciences, SAS has been a member and ardent
supporter of CDISC since 2000. SAS' involvement in CDISC
includes:

• CDISC Board of Directors participation.

• CDISC Industry Advisory Board participation.
• CDISC Data Model Team participation for ODM, ADaM, SDS and CRT-DDS (define.xml).
• Participation in strategic CDISC development initiatives such as the Biomedical Research
Integrated Domain Group (BRIDG) model.
• Interoperability demonstrations in software "connectathons."
• Collaborations in CDISC Interchanges and other projects to explore the interoperability of
CDISC data models.

• Support of CDISC training and implementation activities.

SAS software support for CDISC standards
In addition to helping define CDISC standards, SAS is making certain that our products and
solutions support the implementation of CDISC data standards. SAS®9 includes a component
called PROC CDISC that enables organizations running SAS programs to work with CDISC
structured data. PROC CDISC supports bi-directional conversion of data content contained in a
CDISC ODM XML document to and from SAS-accessible data sources. The current version of
PROC CDISC also supports content validation of SAS-accessible data sources to the CDISC
SDTM data domain definitions. See www.cdisc.org for details on individual format descriptions.
CDISC standards such as SDTM, ODM, LAB and ADaM can be effectively implemented in
solutions like SAS Drug Development and SAS DI Studio, and we're currently exploring additional
ways that these standard processes and data structures can be utilized within our software.

The SAS XML Libname Engine has been enhanced in SAS 9.1.3 to natively read and write
CDISC ODM file content. Using the SAS XML Libname Engine, any data content accessible to
SAS may be converted to a CDISC ODM XML document, or conversely, any content in a CDISC
ODM XML document may be converted to a SAS dataset or other SAS-accessible data source.

SAS CDISC implementation services

In addition to providing CDISC support within our software, SAS consultants are ready to help
your organization implement CDISC standards to drive efficiencies in your clinical development
processes.

Registered solution provider

SAS is recognized by CDISC as a CDISC Registered Solution Provider. Solution providers are
qualified consultants, systems integrators and subject-matter experts believed by CDISC to have
sufficient knowledge and experience implementing the various CDISC standards.

Glossary

ADaM Analysis Dataset Model

CDISC Clinical Data Interchange Standards Consortium
CRT-DDS Case Report Tabulation Data Definition Specification
LAB Laboratory Data Model
ODM Operational Data Model
SDS Submission Data Standards
SDTM Study Data Tabulation Model
XML eXtensible Markup Language